

---

# Right from the Start

## **2022 Zai Lab Trust Report**

This report and all its contents are proprietary to Zai Lab, 2022.

# CONTENTS

- 3 Introduction to Our Trust Report
  - 4 Chief Executive Officer, Samantha Du: Right From the Start
- 5 Who We Are
  - 6 What We Do
  - 6 Our Mission and Values
  - 7 Our Marketed Products
  - 7 Our Offices
- 8 Our ESG Strategy: Trust for Life
- 10 Trust Commitment: Improve Human Health
- 12 Trust Commitment: Create Better Outcomes
- 14 Trust Commitment: Act Right Now
- 16 Appendices
  - 16 Our Alignment with the United Nations Sustainable Development Goals
  - 19 Materiality Matrix
  - 20 Scope 1 & Scope 2 Greenhouse Gas Inventory
  - 21 Sustainability Accounting Standards Board (SASB) Index
  - 23 Global Reporting Initiative (GRI) Content Index
  - 28 Forward-Looking Statements

---

# Introduction to Our Trust Report

In 2021, Zai Lab Limited published our first [Environmental, Social, Governance \(ESG\) Report](#), laying the groundwork for how we strive to act on our commitment to both human and environmental health. In 2022, we have taken significant steps toward measuring our current social and environmental footprint and we are beginning to establish trustworthy goals around ESG so we can build a sustainable pipeline around the world.

With the guidance Business for Social Responsibility, we conducted our first [materiality assessment](#) in 2022 to help us identify, understand, organize, and prioritize ESG themes, opportunities, and risks. The results of which informed the trajectory of our ESG strategy, which we refer to as [Trust for Life](#). This report sheds light on our ESG commitments and progress and highlights our key areas of focus, to help improve the lives of patients with serious diseases in China and around the world.

At Zai Lab, we understand our biggest contribution to society is made through our ability to drive progress and promote good health and well-being in the [Sustainability Accounting Standards Board \(SASB\)](#) specifically centered on the third goal of Good Health and Well-Being. We communicate how we create better outcomes for employees by using [Global Reporting Initiative \(GRI\)](#) Standards and provide transparency regarding our operations using standards outlined by the SASB. Trust for Life is a journey we are excited to build with our stakeholders. If you have any questions, concerns, or ideas, please contact [Jim Massey, Zai Lab Chief Sustainability Officer \(CSO\)](#).



Zai Lab Suzhou, China



## Samantha Du

Founder, Chairperson, and  
Chief Executive Officer

# Right From the Start

The mining of science into medicine is incredibly important to me and why I pursued my PhD in Biochemistry. Since founding Zai Lab, we are dedicated to delivering innovative medicines to people in need, regardless of where they live. To accomplish this ambitious mission, we have established operations in the U.S. and China. Because we work in the intimate space of human health, we are focused on building a company you can trust.

I am thrilled that our pipeline continues to mature and demonstrate first-in-class and best-in-class potential for people who need us. And I am proud of our ability to have established gender and pay equity for Zai Lab people at all levels within the organization.

After reading our 2022 Trust Report, I hope you will find many reasons to place your trust in us too.

The innovation of science and medicine is incredibly important to me on a personal level. And since Zai Lab's inception, we have proudly focused on innovating a company you can trust.

Sincerely,

### **Samantha Du**

Founder, Chairperson, and Chief Executive Officer

# Who We Are


Founded in 2014, Zai Lab advances access to medicine to help address unmet needs of patients with serious diseases including in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience.



These numbers are updated as of October, 2022.

# What We Do

Zai's work is inherently and clearly tied to the pursuit of improving health and concentrates within five areas of expertise. Learn more about [What We Do](#).



**Discovery**



**Development**



**Manufacturing**



**Commercialization**



**Partnership**

# Our Mission and Values

Trust is core to how we operate. We build Trust for Life by never compromising on ethics, integrity, or quality. And we work to provide access to medicines to make a difference for those in need. Our six core values inform the foundation of our Trust for Life approach to ESG. Learn more about [our Mission](#) and [Our Values](#).



# Our Marketed Products

For a deeper understanding of our pipeline growth for the commercially available drugs and clinical trials within Zai Lab's Research and Development, please visit [Our Pipeline](#). And to find out more about our recent drug breakthroughs and achievements, see [Our Press](#).

“

The advancement of Zai's proprietary research pipeline and the diversification of our portfolio presents tremendous opportunities for patients. I am excited to help lead our operations as we scale the company both in China and in the United States.”

**Josh Smiley**

Chief Operating Officer

# Our Offices

Zai Lab has established operations in the following locations across the globe; Shanghai, China, and Cambridge, MA, U.S.; clinical and regulatory offices in Beijing; manufacturing and R&D facilities in Suzhou; and commercial offices in Hong Kong, Taiwan, and Guangzhou.


● Office location



# Our ESG Strategy: Trust for Life

Trust for Life represents how much we value our patients and why we are committed to healthcare innovation. Through Trust for Life, we integrate our ESG strategies into our daily business and operations. This principled approach serves as a powerful expression of our company values and our commitment to do good.

In our effort to sustainably deliver first-in-class medicines to our patients, workforce, health care professionals, communities, and investors, Zai Lab has made three Trust Commitments – **Improve Human Health, Create Better Outcomes**, and **Act Right Now**. This approach is measured and informed by our [Materiality Process](#), as well as significant sustainability benchmarking with raters and rankers, like the 2022 S&P Corporate Sustainability Assessment for the Dow Jones Sustainability Index (DJSI) and commonly accepted standards, like the [Global Reporting Initiative \(GRI\)](#) and [Sustainability Accounting Standards Board \(SASB\)](#). We continue to develop these commitments in collaboration with our partners and stakeholders.



“

Designed to be sustainable from the start, we want to create the roadmap for future businesses to do the same...”

**Samantha Du**

Founder, Chairperson and  
Chief Executive Officer



# TRUST FOR LIFE

**Improve Human Health**

Our patient-first core value drives us to impact human health.

Reach **one million** patients by 2030.

Our values guide us to a healthier, more sustainable future.

**Act Right Now**

We build trust by acting urgently and ethically.

**Complete ERM top-tier risk mitigation plans annually.**

**Create Better Outcomes**

Our ESG approach, commitment to DEI, and growing pipeline help us create better outcomes for everyone.

**Maintain gender equity in leadership and base pay.**

# Improve Human Health

## Commitment

We leverage our core capabilities so we we can support and accelerate development of innovative medicines and therapies. Our pipeline includes four commercially available therapies and 11 internally developed assets with global rights. These complement our partner pipelines, which includes more than 13 later-stage products.

## Target

By 2030, Zai Lab will reach more than one million patients.

<sup>1</sup> As of 1H 2022.  
<sup>2</sup> Data on file.

## Our Approach

### Accelerate Medicines to Patients

Helping more people live better lives.

- ✓ Year to date, we have reached 11,000 patients.<sup>1</sup>
- 🎯 We commit to increase patient access through delivering near universal access for all products at affordable prices.

### Expand Our Global Pipeline

Moving our pipeline from the labs into more lives, faster.

- ✓ We are currently participating in 50 active clinical studies.<sup>2</sup>
- 🎯 We will progress our more than 25 drug candidates (13 in later-stage development).<sup>2</sup>

### Focus on Technology

Creating what is next to improve human health.


- ✓ Leveraging technology, like Schrodinger's proprietary physics-based computation artificial intelligence (AI) drug development platform, to engage healthcare professionals and provide scientific information.
- 🎯 We will use AI and cybersecurity to help us accelerate access the right way.

# Improve Human Health: Journey to Reach One Million Patients

We are expanding and scaling our global pipeline so we can accelerate access to medicines for patients in need. We have already started our journey toward reaching one million lives by 2030.

“ We want to develop a pipeline that creates better outcomes for patients. We want to protect and drive a healthy planet and healthier people. Through that, our principles drive our performance.”

– Jim Massey, Chief Sustainability Officer



- Reach 22,000 patients this year.
- As of 1H2022, we're halfway to our goal, having reached 11,000 patients.\*

Patient Assistant Programs have helped support more than 4,400 patients, as of 1H2022.\*



\* Data on file.

# Create Better Outcomes

## Commitment

In our effort to create better outcomes, we encourage an agile, resilient, and diverse workforce through engagement and fair compensation. We make purposeful contributions to society. We aim to reduce the environmental impact of our business operations and invest in environmental stewardship projects.

## Target

We will continue to maintain gender equity in leadership and base pay at all levels.

## Our Approach

### People

Building an agile, resilient, diverse workforce.

- ✓ We launched the Enterprise Diversity, Equity, and Inclusion (DEI) Counsel and three employee resource communities.
  - Global Women's Leadership Community
  - China Culture and DEI Community
  - US Culture and DEI Community

- 🎯 We will continue to build an agile, resilient, and diverse company.

### Communities

Meaningful engagement with patients, and purposeful contributions to society.

- ✓ We launched our Employee Volunteerism program, providing every Zai Lab employee with eight hours of annual work time to volunteer.
- 🎯 We seek to drive better health outcomes in our communities through product donations and by encouraging our employee volunteerism program.

### Planet Positive

Rooted in environmental protection.

- ✓ We launched our first environmental global partnership with One Tree Planted (OTP) for Earth Day.
- 🎯 In our effort to grow green, we have conducted a [Scope 1 and Scope 2 GHG inventory](#) of our global operations. And in 2023, we commit to launch our Climate Strategy.

# Create Better Outcomes: Through Gender Equity

Proving our dedication to fair compensation to all employees, Zai Lab has achieved base salary equity at all levels of the organization, and we are committed to maintaining it.


“ We are proud that we are creating Zai Lab right from the start. Instead of holding aspirations to make things right in the future—we set targets to maintain doing the right thing.”

— F. Ty Edmondson, Chief Legal Officer

<sup>2</sup> This includes the percentage of all managers (excluding support functions, like HR, IT, Legal, etc.). Decimal percentage rounded up.

<sup>3</sup> Based on the percentage of total STEM positions.

<sup>4</sup> Includes all management positions, including junior, middle, and top management. Decimal percentage rounded up.



# Act Right Now

## Commitment

As we accelerate access to new medicines, we remember that we work in the intimate space of human health. As such, we value the significance of our potential impact. We are committed to driving a culture where our employees work ethically and urgently.

## Target

We will complete enterprise risk management (ERM) plans for top tier risks identified in the annual enterprise risk assessment.



## Our Approach

### What Matters Most

Ethical business culture drives our daily operations.

✓ We launched our new [Code of Business Conduct and Ethics](#) and our [Supplier Code of Conduct](#).

🎯 We will complete ERM top tier risk mitigation plans annually.

### Transparency

Build and disclose business practices across our enterprise.

✓ We launched nine enterprise position statements disclosing commitments, practices, and data. See our [enterprise position statements](#).

🎯 We will improve business and ESG disclosures by aligning with global and regulatory frameworks and participating with annual key raters and rankers, including the Dow Jones Sustainability Index (DJSI), the Carbon Disclosure Project (CDP), and the Task Force on Climate-Related Financial Disclosures (TCFD)

### Performance Management

Reinforce commitment through the inclusion of ESG goals.

✓ We submitted for the first time to the Dow Jones Sustainability Index (DJSI), a recognized best-in-class benchmark for sustainable business practices.


🎯 We will consider other ESG-related targets in future executive compensation decisions.

# Act Right Now: Advancing Transparent and Ethical Business Practices

Our integrity is steeped in how we conduct business worldwide. We are committed to transparency, ethical business practices, and strong governance.

“ We know what we do matters, and that’s why we commit to Act Right Now – balancing a sense of urgency with our standards of ethics and quality.”

- Ann Beasley, Chief Compliance Officer



## Appendices

# Our Alignment with the United Nations Sustainable Development Goals

Zai Lab remains committed to accelerating and expanding our alignment with the United Nations Sustainable Development Goals (SDGs). In our effort to stay in line with our purpose while incorporating our learnings from our materiality assessment, Zai Lab has prioritized the following SDGs:



## Good health and well-being

Ensure healthy lives and promote well-being for all at all ages.

Zai Lab can make a positive impact on the health of the patients we serve. Zai Lab's work is closely aligned with SDG target 3.8: Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality, and affordable essential medicines and vaccines for all. We have multiple products that have been listed with city-affiliated health insurance programs in China, which reduces the financial burden of these medications on local patients. Our goal is to reach one million patients by 2030.

### Affiliated Trust for Life Actions:

- [Accelerate Medicines to Patients](#)
- [Expanding Our Global Pipeline](#)
- [People](#)
- [What Matters Most](#)





## Gender equality

Achieve gender equality and empower all women and girls

Zai Lab strives to achieve gender equality in our organization and has established and maintains female representation in senior management, including the Founder/Chairperson/CEO, and two out of nine members of the Board of Directors. We have established and seek to maintain gender equity in leadership and base pay. In addition to increasing gender equality in our workforce, we also have a Culture Committee dedicated to opportunities for all employees who identify as women.

### **Affiliated Trust for Life Actions:**

[People](#)



## Industry, innovation, and infrastructure

Build resilient infrastructure, promote sustainable industrialization and foster innovation

Zai Lab works to bring innovative medicines to people in need around the world, and to do so in an inclusive, sustainable manner. Given that we are a biopharmaceutical company, our most substantial reach is through improving people's health. Innovation through the medicines we create is how we encourage greater accessibility and inclusivity.

### **Affiliated Trust for Life Actions:**

[Accelerate Medicines to Patients](#)

[Expanding Our Global Pipeline](#)

[Focus on Technology](#)

[Communities](#)

[Transparency](#)

[Performance Management](#)



## Responsible consumption and production

Ensure sustainable consumption and production patterns

In addition to our direct operations, Zai Lab is committed to ensuring our supply chain operates in an ethical, transparent, and sustainable manner. Following our 2022 Materiality Assessment, we are committed to responsible procurement and having an integrated sustainable supply chain are core performance and value drivers. To promote responsible consumption and production, we have established a [Supplier Code of Conduct](#).

**Affiliated Trust for Life Actions:**

[Accelerate Medicines to Patients](#)  
[Expanding Our Global Pipeline](#)  
[Communities](#)



## Climate action

Take urgent action to combat climate change and its impacts

We recognize that our daily business operations matter in the journey to address global environmental issues, including climate change, resource scarcity, and biodiversity loss. As an overarching goal, we are committed to reducing the environmental impact of our operations and investing in stewardship projects. In 2022, Zai Lab conducted a [Scope 1 and Scope 2 GHG inventory](#). And by 2023, we plan to achieve a complete Scope 1, 2, and 3 Inventory.

**Affiliated Trust for Life Actions:**

[Planet Positive](#)

# Materiality Matrix

The Materiality Report was conducted in 2022 and informs our ESG strategy, Trust for Life. The interactive matrix below illustrates our areas of focus within each Commitment. If you would like to learn more, please contact [Jim Massey](#).



# Scope 1 & Scope 2 Greenhouse Gas Inventory

Our 2021 GHG inventory was based on a thorough review of Zai Lab assets, facilities, and operations, following the GHG Protocol, and will serve as a GHG emissions baseline to measure and set our future GHG reduction targets.

Scope 1\*

**28.4 (1%)**

Metric Tons of CO2e

Scope 2—Market based\*\*

**3,536.6 (99%)**

Metric Tons of CO2e

Scope 2—Location based\*\*\*

**3,548.5 (99%)**

Metric Tons of CO2e

\* When data was not available, industry-leading estimations and perimeters were used.

\*\* Market-based Scope 2 emissions calculated using the emissions factors reflecting the renewable energy of purchased electricity.

\*\*\* Location-based Scope 2 emissions calculated using the average emission factors of purchased electricity.

# Sustainability Accounting Standards Board (SASB) Index

This report includes our responses to certain SASB Standards for the Biotechnology & Pharmaceuticals industry within the Health Care sector and indicates where additional information on certain topics may be found. All data are for the year ended December 31, 2021, unless otherwise noted.

Topic	Code	Description	Response
<b>Safety of Clinical Trial Participants</b>	HC-BP-210a.1.	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	We follow the International Council for Harmonization Good Clinical Practice (ICH-GCP).
	HC-BP-210a.2.	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	We did not have any FDA Sponsored Inspections related to clinical trial management and pharmacovigilance that resulted in a VAI or OAI.
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	We disclose material legal proceedings in our 2021 Annual Report (see pg. 157). <a href="#">Clinical Trial Research and Transparency</a>
<b>Access to Medicines</b>	HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Zai Lab's commercial operations focused on the Greater China Region (GCR), including mainland China, Hong Kong, Taiwan, and Macau. We did not benchmark commercial operations against the Access to Medicine Index.
	HC-BP-240a.2.	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	<a href="#">Access to Medicines &amp; Affordability and Pricing</a>
<b>Affordability &amp; Pricing</b>	HC-BP-240b.1.	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic products to market for a defined time period	We disclose material legal proceedings in our <a href="#">2021 Annual Report</a> , pg. 157.
	HC-BP-240b.2.	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	N/A. Zai Lab did not market any products in the United States. For information on our commercial products and markets. See our <a href="#">2021 Annual Report</a> , pg. 3-7.
	HC-BP-240b.3.	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Not reported <a href="#">Commitment to Ethical Marketing Practices</a>
<b>Drug Safety</b>	HC-BP-250a.1.	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	N/A. Zai Lab does not market any products in the United States and has no drugs in the FDA's database.
	HC-BP-250a.2.	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Thus, has not reported any events in the FDA Adverse Event Reporting System.
	HC-BP-250a.3.	Number of recalls issued; total units recalled	None.
	HC-BP-250a.4.	Total amount of product accepted for take-back, reuse, or disposal	None.
	HC-BP-250a.5.	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	None. <a href="#">2021 ESG Report</a> , pg. 48

Topic	Code	Description	Response
<b>Counterfeit Drugs</b>	HC-BP-260a.1.	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	To prevent product counterfeiting, Zai lab places anti-counterfeit seal labels on two sides of each product carton. In addition, an anti-counterfeit line on the carton can be found by macrophotograph. Every carton has its own drug traceability code that can be used to trace the complete distribution process from factory to market.
	HC-BP-260a.2.	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	We would immediately alert our customers and business partners when a counterfeit product is identified and take necessary action in preventing it from harming patients.
	HC-BP-260a.3.	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	No legal actions or arrests have occurred in relation to counterfeit products. <a href="#">2021 ESG Report</a> , pg. 49
<b>Ethical Marketing</b>	HC-BP-270a.1.	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	We disclose material legal proceedings in our 2021 Annual Report (see pg 157).
	HC-BP-270a.2.	Description of code of ethics governing promotion of off-label use of products	<a href="#">Commitment to Ethical Marketing Practices</a> <a href="#">Supply Chain Collaboration</a> <a href="#">Clinical Trial Research and Transparency</a> <a href="#">Code of Business Conduct and Ethics</a>
<b>Employee Recruitment, Development &amp; Retention</b>	HC-BP-330a.1.	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	<a href="#">Workforce Engagement and Development</a> <a href="#">2021 ESG Report</a> , pg. 25-26 <a href="#">2021 Annual Report</a> , pg. 78-79.
	HC-BP-330a.2.	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	Not reported. <a href="#">Workforce Engagement and Development</a>
<b>Supply Chain Management</b>	HC-BP-430a.1.	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	We do not participate in the RX-360 International Pharmaceutical Supply Chain Consortium. <a href="#">Supply Chain Collaboration</a>
<b>Business Ethics</b>	HC-BP-510a.1.	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	We disclose material legal proceedings in our 2021 Annual Report (see pg. 157).
	HC-BP-510a.2.	Description of code of ethics governing interactions with health care professionals	<a href="#">Code of Business Conduct and Ethics</a> <a href="#">Commitment to Ethical Marketing Practices</a>

# Global Reporting Initiative (GRI) Content Index

In this report, we disclose indicators informed by the Global Reporting Initiative (GRI) Standard for the period October 2021 – October 2022. The following index lists indicators from our targeted SDGs in relation to GRI Standards, on which we have fully or partially reported. Links go to our website.

GRI Indicator	Disclosure Title	Reference	SDG
<b>GRI 102: GENERAL DISCLOSURES</b>			
102-1	Name of the organization	Introduction, pg. 3	
102-2	Activities, brands, products, and services	What We Do, pg. 6 Our Marketed Products, pg. 7	
102-3	Location of headquarters	Our Offices, pg. 7	
102-4	Location of operations	Our Offices, pg. 7	
102-5	Ownership and legal form	<a href="#">Leadership</a> <a href="#">2021 Annual Report on Form 10-K</a>	
102-6	Markets served	Our Marketed Products, pg. 7 Our Offices, pg. 7 <a href="#">2021 Annual Report on Form 10-K</a>	
102-7	Scale of the organization	Our Offices, pg. 7 <a href="#">Workforce Engagement and Development</a>	
102-8	Information on employees and other workers	Improve Human Health, Journey to Reach One Million Patients, pg. 11 <a href="#">About Us</a>	
102-9	Supply Chain	Our Offices, pg. 7 Our Marketed Products, pg. 7 Act Right Now – Transparency, pg. 14 Improve Human Health, Journey to Reach One Million Patients, pg. 11 <a href="#">Supply Chain Collaboration</a>	Goal 9: Industry, Innovation, and Infrastructure Goal 12: Responsible Consumption and Production Goal 13: Climate Action

GRI Indicator	Disclosure Title	Reference	SDG
102-10	Significant changes to the organization and its supply chain	Act Right Now – Transparency, pg. 14 Improve Human Health, Journey to Reach One Million Patients, pg. 11 <a href="#">2021 Annual Report on Form 10-K</a> <a href="#">Supply Chain Collaboration</a>	Goal 5: Gender Equity Goal 9: Industry, Innovation, and Infrastructure Goal 12: Responsible Consumption and Production
102-11	Chair of the highest governance body	<a href="#">Founder, Chairperson and Chief Executive Officer</a>	
102-12	External initiatives	What We Do, pg. 6 Our Marketed Products, pg. 7 <a href="#">Corporate Social Responsibility</a>	
102-14	Statement from senior decision-maker	Chief Executive Officer, Samantha Du: Doing It Right, From the Start, pg. 4	
102-16	Values, principles, standards, and norms of behavior	Chief Executive Officer, Samantha Du: Doing It Right, From the Start, pg. 4 Our Mission and Values, pg. 6 What We Do, pg. 6 Trust for Life, pg. 8 <a href="#">Our Mission</a> <a href="#">Our Values</a> <a href="#">Our Position</a> <a href="#">Our Code of Business Conduct and Ethics</a>	Goal 3: Good Health and Well-Being
102-20	Executive-level responsibility for economic and environmental and social topics	Chief Executive Officer, Samantha Du: Doing It Right, From the Start, pg. 4 Our Mission and Values, pg. 6	
102-22	Statement on sustainable development strategy	Chief Executive Officer, Samantha Du: Doing It Right, From the Start, pg. 4 Our Mission and Values, pg. 6	Goal 3: Good Health and Well-Being Goal 5: Gender Equity Goal 12: Responsible Consumption and Production
102-23	Policy commitments	Trust for Life, pg. 8 Our Alignment with SDGs, pg. 16 <a href="#">Our Code of Business Conduct and Ethics</a> <a href="#">Position Statements</a>	
102-24	Embedding policy commitments	Trust for Life, pg. 8 Our Alignment with SDGs, pg. 16	Goal 3: Good Health and Well-Being Goal 5: Gender Equity Goal 9: Industry, Innovation, and Infrastructure Goal 12: Responsible Consumption and Production Goal 13: Climate Action



GRI Indicator	Disclosure Title	Reference	SDG
103-1	Explanation of the material topic and its boundary	Our Materiality Matrix, pg. 19	
103-2	The management approach and its components	Trust for Life, pg. 8	
103-3	Evaluations of the management approach	The disclosure of the management approach for each material topic meets or exceeds the requirements of the GRI 103 Management approach requirement.	
201-1	Direct economic value generated and distributed	<a href="#">2021 Annual Report on Form 10-K</a>	Goal 5: Gender Equity Goal 9: Industry, Innovation, and Infrastructure Goal 12: Responsible Consumption and Production
201-2	Financial implications and other risks and opportunities due to climate change	Create Better Outcomes – Planet Positive, pg. 12 <a href="#">2021 Annual Report on Form 10-K</a>	Goal 12: Responsible Consumption and Production Goal 13: Climate Action
201-3	Defined benefit plan obligations and other retirement plans	<a href="#">2021 Annual Report on Form 10-K</a>	Goal 3: Good Health and Well-Being Goal 5: Gender Equity
205-2	Communication and training in anticorruption policies and procedures	Act Right Now, pg. 14 <a href="#">Supplier Code of Conduct</a>	
302-1	Energy consumption within the organization	<a href="#">Climate Change and Environmental Stewardship</a> GHG Inventory, pg. 20	Goal 12: Responsible Consumption and Production
302-2	Energy consumption outside of the organization	Zai Lab does not track energy consumption outside of the organization but will determine how we can more responsibly steward our impact on external consumption.	Goal 12: Responsible Consumption and Production
305-1	Direct (Scope 1) GHG emissions	Zai Lab has begun tracking our Scope 1 GHG emissions. We are working to develop and establish processes to mitigate our impact on this emission.	Goal 3: Good Health and Well-Being Goal 12: Responsible Consumption and Production Goal 13: Climate Action
305-2	Energy indirect (Scope 2) GHG emissions	Zai Lab has begun tracking our Scope 1 GHG emissions. We are working to develop and establish processes to mitigate our impact on this emission.	Goal 3: Good Health and Well-Being Goal 13: Climate Action

GRI Indicator	Disclosure Title	Reference	SDG
403-1	Occupational health and safety management system	<a href="#">Occupational Health and Safety 2021 Annual Report on Form 10-K</a>	
403-2	Hazard identification, risk assessment and incident investigation	<a href="#">2021 Annual Report on Form 10-K</a>	
403-5	Worker training on occupational health and safety	<a href="#">2021 Annual Report on Form 10-K</a>	
403-9	Work-related injuries	<a href="#">2021 Annual Report on Form 10-K</a>	Goal 3. Good Health and Well-Being
404-2	Programs for upgrading employee skills and transition assistance programs	<a href="#">Workforce Engagement &amp; Development</a>	
405-1	Diversity of governance bodies and employees	<a href="#">2021 Annual Report on Form 10-K</a> _ <a href="#">Workforce Engagement &amp; Development</a>	Goal 5. Gender Equality
405-2	Ratio of basic salary and remuneration of women to men	<a href="#">Workforce Engagement &amp; Development</a>	Goal 5. Gender Equality
413-1	Operations with local community engagement, impact assessments, and development programs	Create Better Outcomes – People, Communities, pg. 12 <a href="#">Corporate Social Responsibility</a> <a href="#">Workforce Engagement &amp; Development</a>	
414-1	New suppliers that were screened using social criteria	Act Right Now – Transparency, pg. 14 <a href="#">Supplier Code of Conduct</a>	
418-1	Substantiated complaints concerning breaches of customer privacy and losses of customer data	None.	

# Forward-Looking Statements

This report contains statements about future expectations, plans, and prospects for Zai Lab, including, without limitation, statements regarding our ability to advance our clinical pipeline and further demonstrate our commercial and discovery capabilities, expected milestones for our products and product candidates, and other statements containing words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this presentation and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) the effects of the coronavirus (COVID-19) pandemic, including any government actions or lockdown measures taken in response, on our business and general economic, regulatory and political conditions, (6) risks related to doing business in China, and (7) other factors discussed in our most recent annual and quarterly reports and other reports we have filed with the U.S. Securities and Exchange Commission.

We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this presentation. Our SEC filings can be found on our website at [www.zailaboratory.com](http://www.zailaboratory.com) and on the SEC’s website at <http://www.sec.gov>. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities of Zai Lab, Limited.

